Mahamaya Lifesciences has scheduled its 24th Annual General Meeting for September 29, 2026. The meeting will address critical governance changes, including a major leadership redesignation and substantial remuneration revisions for key management personnel.

The company will hold the meeting via Video Conferencing or Other Audio Visual Means, in compliance with Ministry of Corporate Affairs circulars. Shareholders holding shares as of the cut-off date of September 23, 2026, will be eligible to vote through remote e-voting facilitated by Central Depository Services (India) Limited.

Leadership Redesignations

The most significant agenda item involves a structural shift in executive leadership effective November 1, 2026. Mr. Krishnamurthy Ganesan will relinquish his position as Managing Director to assume the role of Executive Director and Chairman of the Board. Concurrently, Mr. Prashant Krishnamurthy, currently serving as Executive Director and Chief Financial Officer, will be elevated to the position of Managing Director for a five-year term.

These changes aim to facilitate succession planning and strategic leadership continuity within the agrochemical manufacturer. The Board of Directors approved these recommendations based on inputs from the Nomination and Remuneration Committee.

Remuneration Revisions

Shareholders are asked to approve special resolutions revising the compensation packages for the redesigned roles and other key directors:

The proposed salary increments are capped at 15% annually from FY28 onwards, subject to profit availability. In the event of losses or inadequate profits, remuneration will be paid as minimum statutory allowances under Schedule V of the Companies Act, 2013.

Independent Director Appointments

The AGM will also regularize the appointment of Mr. Bhagirath Choudhary as an Independent Director for a three-year term starting August 25, 2026. Additionally, shareholders must approve the re-appointment of Dr. Gopal Krishna Raju and Dr. Charudatta Digambar Mayee as Independent Directors for second terms commencing December 11, 2026.

A specific resolution seeks approval for Dr. Charudatta Digambar Mayee to continue his directorship beyond the age of 75, citing his unimpaired capability and rich professional background in agricultural biotechnology.

Financial Context

While the notice focuses on governance, it includes financial performance data for FY26 to contextualize the remuneration approvals. The company reported revenue from operations of ₹32,887.30 lakh in FY26, up from ₹26,414.86 lakh in FY25. Profit after tax rose to ₹1,652.33 lakh from ₹1,281.16 lakh in the prior year.

What the Numbers Show

The proposed managerial remuneration represents a significant increase relative to the company's profit base. The combined fixed salaries for the three key promoters—Mr. Prashant Krishnamurthy, Mr. Krishnamurthy Ganesan, and Mrs. Lalitha Krishnamurthy—total ₹2.95 crore annually. This figure constitutes approximately 17.8% of the reported Profit After Tax of ₹1,652.33 lakh for FY26. This high ratio underscores the reliance on promoter-led management and the substantial cost burden of executive compensation relative to net earnings.

Mahamaya Lifesciences reported a 24.5% year-on-year increase in revenue from operations to ₹328.87 crore for the financial year ended March 31, 2026. The agrochemical manufacturer also saw its consolidated profit after tax (PAT) rise 29.0% to ₹16.52 crore, driven by strong operational execution and margin expansion.

The company’s EBITDA grew 32.6% to ₹34.26 crore, with the EBITDA margin expanding to 10.42% from 9.78% in the previous fiscal. This improvement occurred alongside a 24.5% revenue growth, indicating effective cost management and operational leverage during the period.

Financial Performance

Mahamaya Lifesciences posted a profit before tax (PBT) of ₹23.87 crore, up 38.4% from ₹17.25 crore in FY25. The basic earnings per share (EPS) improved to ₹8.33 from ₹7.52 in the prior year. The company retained the entire profit for the year, declaring no dividend.

Balance Sheet Strengthening

The company listed on the BSE SME Platform in November 2025 through an Initial Public Offering (IPO). The fresh issue raised ₹64.28 crore, significantly strengthening the balance sheet. Shareholders’ funds increased to ₹12,192.99 lakh, while the net debt-to-equity ratio improved to 0.74x from 1.18x in the previous year. Cash and cash equivalents rose sharply to ₹393.99 lakh from ₹39.95 lakh.

What the Numbers Show

The divergence between revenue growth (24.5%) and EBITDA growth (32.6%) highlights improved operating efficiency. While finance costs rose 19.7% to ₹8.14 crore due to higher borrowings supporting expansion, the company maintained robust interest coverage. The significant drop in other income (down 61.9% to ₹1.15 crore) underscores that the PAT growth was driven primarily by core operational performance rather than non-recurring gains.

Strategic Outlook

Management highlighted the favourable industry outlook and the company’s transition into a publicly listed entity as key milestones. Strategic priorities include expanding manufacturing capabilities at its Dahej facility, developing active-ingredient process development, and deepening international market presence. The company plans to utilize unutilized IPO proceeds for technical manufacturing plants and formulation facility expansions.